Successful Completion of Targeted Share Issue by Arco Vara AS
On 5 June 2025, the Annual General Meeting of Arco Vara AS adopted the decision to issue a targeted share offering to specific investors in order to increase the company's share capital.Arco Vara AS announces that the targeted share issue approved by the shareholders has been successfully ...
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
Basel, June 12, 2025 - Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® ( iptacopan ) in adult patients with paroxysmal nocturnal hemoglobinuria ( PNH ) with Hb levels ≥10g/dL who switched from ...
KN Energies signs Grant Agreement with the European Commission
International energy terminal operator AB KN Energies ( hereinafter - KN, the Company ) has signed a Grant Agreement with the European Commission to conduct technical and commercial studies for a planned CO2 terminal in Klaipėda.
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - Editas Medicine ( NASDAQ:EDIT )
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta ...
US Bancorp studying stablecoins as crypto custody arm sees revival
U.S. Bancorp CEO Gunjan Kedia says her bank is looking into stablecoins as its crypto custody business bounces back after struggling under Biden.
